A New Path to Drug Discovery
Bi-XDC technology empowers currently undruggable molecules and targets, transforming them into druggable entities. Designed to tackle substantial unmet medical needs in cancer and beyond, Bi-XDC offers a promising solution for advancing healthcare.
Coherent Biopharma
a company pioneering and developing Bi-targeting XDC technology
1 Proprietary Platform Technology
5+ First-in-Class Assets
15+ Global IP Protection
5+ Top scientists & industry experts.
110+ Expert professionals.
5 Potential First-in-Class
10+ Products
10+ Oncology Indication Clinical Trials
Integrated management organization in China, the U.S and Australia.
Breaking News
在近日举行的BioChina大会上，XDC（偶联药物）作为肿瘤治疗的前沿领域备受瞩目。同宜医药创始人、CEO黄保华博士受邀出席专家嘉宾访谈，深入剖析了XDC赛道的差异化竞争策略。黄博士指出，XDC是真正具备“源头创新”属性的领域，行业同仁应如“八仙过海”各显神通，利用自身技术特点开发出能够“改变临床实践（Practice Changing）甚至具备治愈潜力（Curative）”的药物。
Pamplona Therapeutics and Coherent Biopharma today announced a strategic collaboration to combine Pamplona’s AI-driven targeted...
日前，同宜医药（苏州）有限公司与南京科络思生物科技有限公司在南京科络思生物总部签署全面战略合作协议。